Silver Book Fact

According to the Pharmaceutical Research and Manufacturers of America, a medicine in development that is a monoclonal antibody, targets the epidermal growth factor receptor. Because cancer cells can become dependent on the growth signals that are mediated through the epidermal growth factor receptor, blocking it may stop the growth of cancer cells and eradicate existing cancer cells.

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • Drugs like bevacizumab- designed to impede the growth of blood vessels and tumors- can cost more than $100,000 per patient.   
  • A 10 percent reduction in cancer-related deaths in the U.S. would be worth an estimated $4.4 trillion to current and future generations.  
  • A drug that can reduce the risk of breast cancer in high-risk women costs approximately $1,050 per year. The average cost per year for surgery or other invasive methods of…  
  • As of July 2014, 18 anticancer drugs received FDA approval after being designated breakthrough therapies.  
  • “Knowing that his disease had a high cure rate, Ben Dacus felt a sense of security at a time of great uncertainty. In 1988 he was diagnosed with Hodgkin’s disease. Strangely…